The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Double-blind randomized trial of aflibercept versus placebo with docetaxel and prednisone for treatment of metastatic castration-resistant prostate cancer (mCRPC).
Ian Tannock
Consultant or Advisory Role - Sanofi (U)
Research Funding - Sanofi
Karim Fizazi
Consultant or Advisory Role - Sanofi
Sergey Ivanov
No relevant relationships to disclose
Camilla Thellenberg-Karlsson
No relevant relationships to disclose
Aude Flechon
No relevant relationships to disclose
Iwona Anna Skoneczna
Honoraria - Sanofi
Francisco Jorquera Orlandi
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
Gwenaelle Gravis
No relevant relationships to disclose
Vsevolod Matveev
No relevant relationships to disclose
Sevil E. Bavbek
No relevant relationships to disclose
Thierry Gil
No relevant relationships to disclose
Luciano S. Viana
No relevant relationships to disclose
Osvaldo Aren
No relevant relationships to disclose
Oleg Karyakin
No relevant relationships to disclose
Tony Elliott
Honoraria - Sanofi
Alison J. Birtle
No relevant relationships to disclose
Emmanuelle Magherini
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Daniel Peter Petrylak
Consultant or Advisory Role - Sanofi
Bertrand Tombal
Honoraria - Sanofi
Mark Rosenthal
Consultant or Advisory Role - Sanofi